Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PRRG4 (ImmuneEditome ID:79056)

1. Gene summary of enriched editing regions for PRRG4

Gene summary

Gene information	Gene symbol	PRRG4
	Gene ID	79056
	GeneSynonyms	PRGP4\|TMG4
	GeneCytomap	11p13
	GeneType	protein-coding
	GeneDescription	transmembrane gamma-carboxyglutamic acid protein 4\|proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane)\|proline-rich Gla protein 4\|proline-rich gamma-carboxyglutamic acid protein 4
	GeneModificationdate	20230329
	UniprotID	Q9BZD6;A0A0S2Z5N9
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr11:32845868-32846785:+	ENST00000257836.3	ENSG00000135378.3	PRRG4	intronic	AluSc,AluJr,AluJb,(TAA)n,L2b	chr11:32845868-32846785:+.alignment
chr11:32853548-32854557:+	ENST00000257836.3	ENSG00000135378.3	PRRG4	UTR3	GA-rich,AluSg,AluSx1	chr11:32853548-32854557:+.alignment
chr11:32856848-32857461:+	ENST00000257836.3	ENSG00000135378.3	PRRG4	UTR3	AluSx1,AluJb	chr11:32856848-32857461:+.alignment

Top

2. Tumor-specific enriched editing regions for PRRG4

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000135378.3,PRRG4	BRCA	EAG	2.8202e-02
chr11:32853548-32854557:+	KIRC	EER	1.5059e-03
chr11:32856848-32857461:+	LIHC	EER	1.8433e-05
ENSG00000135378.3,PRRG4	LIHC	EAG	3.9620e-06

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for PRRG4

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for PRRG4

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000135378.3,PRRG4

LIHC

EAG

ENSG00000149929.11

chr16

29993648:29993808:29993905:29994843:29995102:29995217

-0.2967

2.2201e-04

4.3580e-13

-0.4279

CNBP;CSTF2T;DDX54;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;IGF2BP1;IGF2BP2;IGF2BP3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;RANGAP1;RBM10;SRSF1;SRSF9;TAF15;U2AF2;UPF1;ZNF184

Dendritic_cells_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000172053.10

chr3

49099109:49099253:49099343:49099431:49099593:49099647:49099760:49099853

0.3011

2.7955e-04

2.6865e-13

0.4299

ADAR;CNBP;CSTF2T;DDX54;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;RANGAP1;RBM10;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000137154.8

chr9

19376284:19376388:19376493:19376589:19378707:19378918:19379486:19379618

0.2911

5.7563e-04

7.0270e-12

0.4057

ADAR;CNBP;CSTF2T;DDX54;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;RANGAP1;RBM10;RBM47;RC3H1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZC3H7B;ZNF184

RPS6

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000137154.8

chr9

19376284:19376388:19376493:19376646:19378707:19378918:19379486:19379618

0.2911

5.7563e-04

7.0270e-12

0.4057

RPS6

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000197070.9

chr9

137613614:137613769:137614031:137614898:137614898:137615000:137615073:137615360

-0.2827

9.4966e-04

7.5959e-12

-0.4051

ADAR;CNBP;CSTF2T;DDX54;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LARP4B;LIN28;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;PUM2;RANGAP1;RBM10;SRSF1;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000197070.9

chr9

137613614:137613769:137614031:137614898:137614922:137615000:137615073:137615360

-0.2821

9.9070e-04

8.5730e-12

-0.4041

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000104872.6

chr19

49447826:49447908:49448000:49448059:49449478:49449654:49450781:49450836

0.2761

1.4259e-03

5.0365e-12

0.4082

ADAR;CNBP;CSTF2T;DDX54;DICER1;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;RANGAP1;RBM10;SRSF1;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZNF184

Macrophages_M1

GSVA_HALLMARK_UV_RESPONSE_DN

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000177885.9

chr17

75318075:75318297:75318754:75318796:75320331:75320553:75321658:75321753

0.2703

1.5302e-03

5.9444e-20

0.5232

ADAR;CNBP;CSTF2T;DDX54;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPD;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;PUM2;RANGAP1;RBM10;RBM47;RC3H1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZC3H7B;ZNF184

T_cells_gamma_delta

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000136156.8

chr13

48256176:48256383:48258125:48258236:48258910:48258947:48261138:48261388

-0.2712

1.9021e-03

1.1195e-12

-0.4195

ADAR;CNBP;CSTF2T;DDX54;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPD;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PTBP1;PUM2;RANGAP1;RBM10;RBM47;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZC3H7B;ZNF184

ITM2B

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000135378.3,PRRG4

LIHC

EAG

MEX

ENSG00000111229.11

chr12

110434909:110435217:110436109:110436204:110440311:110440388:110445451:110445485

0.2698

2.0699e-03

3.5539e-12

0.4109

ADAR;CNBP;CSTF2T;DDX54;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBM10;RBM47;RC3H1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;U2AF2;UPF1;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

5. Enriched editing regions and immune infiltration for PRRG4

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr11:32856848-32857461:+	BLCA	EER	B_cells_naive	9.1511e-04	0.2762
ENSG00000135378.3,PRRG4	BLCA	EAG	B_cells_naive	3.9549e-04	0.2571
chr11:32856848-32857461:+	CESC	EER	Plasma_cells	4.7253e-02	0.2268
chr11:32856848-32857461:+	COAD	EER	Eosinophils	1.5577e-05	0.5152
ENSG00000135378.3,PRRG4	COAD	EAG	Eosinophils	2.1402e-04	0.4150
chr11:32853548-32854557:+	ESCA	EER	T_cells_gamma_delta	2.7304e-06	0.4787
chr11:32856848-32857461:+	ESCA	EER	Dendritic_cells_resting	2.5615e-02	-0.2029
ENSG00000135378.3,PRRG4	ESCA	EAG	T_cells_gamma_delta	2.4393e-02	0.1930
chr11:32856848-32857461:+	GBM	EER	Plasma_cells	3.9940e-02	0.4312
ENSG00000135378.3,PRRG4	GBM	EAG	T_cells_CD4_memory_activated	2.6299e-02	0.4528
chr11:32853548-32854557:+	HNSC	EER	NK_cells_activated	2.4087e-03	0.3431
chr11:32856848-32857461:+	HNSC	EER	NK_cells_activated	2.3299e-03	0.2544
ENSG00000135378.3,PRRG4	HNSC	EAG	NK_cells_activated	4.6208e-04	0.2642
chr11:32853548-32854557:+	KIRC	EER	T_cells_regulatory_(Tregs)	1.1506e-02	0.1917
ENSG00000135378.3,PRRG4	KIRC	EAG	T_cells_regulatory_(Tregs)	1.1737e-03	0.1990
chr11:32856848-32857461:+	LIHC	EER	T_cells_gamma_delta	6.3343e-03	0.1772
ENSG00000135378.3,PRRG4	LIHC	EAG	T_cells_gamma_delta	1.5344e-02	0.1491
chr11:32853548-32854557:+	LUAD	EER	NK_cells_activated	5.2896e-03	0.2690
ENSG00000135378.3,PRRG4	LUSC	EAG	Macrophages_M1	1.6980e-02	0.1543
chr11:32853548-32854557:+	OV	EER	T_cells_CD4_naive	1.7875e-02	0.1912
chr11:32856848-32857461:+	OV	EER	T_cells_CD8	1.9763e-02	0.1660
ENSG00000135378.3,PRRG4	OV	EAG	T_cells_follicular_helper	2.4324e-02	-0.1494
chr11:32856848-32857461:+	PAAD	EER	Mast_cells_activated	2.3550e-02	0.2426
ENSG00000135378.3,PRRG4	PAAD	EAG	Mast_cells_activated	3.4797e-02	0.2180
chr11:32856848-32857461:+	PRAD	EER	T_cells_CD4_memory_resting	1.6601e-02	-0.2391
ENSG00000135378.3,PRRG4	PRAD	EAG	T_cells_regulatory_(Tregs)	1.5240e-03	0.2785
chr11:32853548-32854557:+	STAD	EER	Mast_cells_activated	2.8584e-06	0.3151
chr11:32856848-32857461:+	STAD	EER	B_cells_naive	1.7670e-03	0.2203
ENSG00000135378.3,PRRG4	STAD	EAG	Plasma_cells	6.0986e-04	0.2069
chr11:32853548-32854557:+	THCA	EER	B_cells_memory	3.4815e-02	0.1839
ENSG00000135378.3,PRRG4	THCA	EAG	B_cells_naive	4.2642e-02	-0.1198
ENSG00000135378.3,PRRG4	THYM	EAG	T_cells_follicular_helper	1.3226e-02	0.3628
ENSG00000135378.3,PRRG4	UCEC	EAG	Macrophages_M1	1.4393e-02	-0.2835

Top

6. Enriched editing regions and immune gene sets for PRRG4

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000135378.3,PRRG4	COAD	EAG	2.1781e-05	-0.4692	2.5501e-03	-0.3435	3.6997e-05	-0.4574	2.9758e-02	-0.2511

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr11:32856848-32857461:+	BLCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	5.8623e-04	-0.2860
ENSG00000135378.3,PRRG4	BLCA	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	3.0617e-03	-0.2160
chr11:32853548-32854557:+	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	9.3060e-03	-0.1504
ENSG00000135378.3,PRRG4	BRCA	GSVA_HALLMARK_HEME_METABOLISM	EAG	7.8641e-06	-0.1816
chr11:32856848-32857461:+	CESC	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.5498e-03	0.3547
ENSG00000135378.3,PRRG4	CESC	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.2312e-02	0.2586
ENSG00000135378.3,PRRG4	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	4.4171e-07	-0.5445
chr11:32856848-32857461:+	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	4.3914e-06	-0.5424
chr11:32853548-32854557:+	ESCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.0359e-03	-0.3053
ENSG00000135378.3,PRRG4	ESCA	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.2594e-02	-0.2135
chr11:32856848-32857461:+	ESCA	GSVA_HALLMARK_APICAL_SURFACE	EER	4.5037e-02	-0.1826
chr11:32856848-32857461:+	HNSC	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.2469e-02	-0.2099
ENSG00000135378.3,PRRG4	HNSC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	9.7105e-04	-0.2494
chr11:32853548-32854557:+	HNSC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.4405e-03	-0.3592
chr11:32853548-32854557:+	KIRC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.1878e-03	-0.2445
chr11:32856848-32857461:+	KIRC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	2.5981e-05	-0.2839
ENSG00000135378.3,PRRG4	KIRC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.3776e-05	-0.2645
ENSG00000135378.3,PRRG4	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.1986e-02	-0.2388
chr11:32856848-32857461:+	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	5.3472e-06	0.2913
chr11:32853548-32854557:+	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.1394e-04	-0.3357
ENSG00000135378.3,PRRG4	LIHC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	6.7524e-08	-0.3247
chr11:32853548-32854557:+	LUAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.2292e-03	-0.2835
ENSG00000135378.3,PRRG4	LUAD	GSVA_HALLMARK_PEROXISOME	EAG	4.5622e-03	-0.1825
chr11:32856848-32857461:+	LUAD	GSVA_HALLMARK_ADIPOGENESIS	EER	4.7487e-02	-0.1403
ENSG00000135378.3,PRRG4	LUSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.1463e-03	-0.2091
chr11:32856848-32857461:+	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.1387e-02	-0.1606
ENSG00000135378.3,PRRG4	OV	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	2.1751e-03	0.2024
chr11:32856848-32857461:+	OV	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	3.7589e-03	0.2056
chr11:32853548-32854557:+	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.8882e-03	-0.2321
ENSG00000135378.3,PRRG4	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	6.4174e-03	0.5878
chr11:32856848-32857461:+	PRAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	1.1494e-03	-0.3205
ENSG00000135378.3,PRRG4	PRAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.4393e-05	-0.3745
ENSG00000135378.3,PRRG4	READ	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	4.6347e-02	-0.4392
chr11:32856848-32857461:+	SARC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.2924e-04	-0.5190
ENSG00000135378.3,PRRG4	SARC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.4891e-04	-0.4804
ENSG00000135378.3,PRRG4	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	2.8947e-02	0.3002
chr11:32856848-32857461:+	SKCM	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	8.9754e-03	-0.3984
ENSG00000135378.3,PRRG4	STAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	7.8548e-03	0.1612
chr11:32856848-32857461:+	STAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	5.2772e-03	0.1970
ENSG00000135378.3,PRRG4	THCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	4.9974e-04	-0.2042
chr11:32853548-32854557:+	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	2.0609e-02	-0.2014
chr11:32856848-32857461:+	THCA	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EER	5.2970e-03	-0.1904
ENSG00000135378.3,PRRG4	THYM	GSVA_HALLMARK_APICAL_SURFACE	EAG	2.4791e-04	-0.5153
ENSG00000135378.3,PRRG4	UCEC	GSVA_HALLMARK_HEME_METABOLISM	EAG	4.1018e-04	-0.4003
chr11:32853548-32854557:+	UCEC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.4423e-02	-0.4832
chr11:32856848-32857461:+	UCEC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.0058e-03	-0.3910

Top

7. Enriched editing regions and drugs for PRRG4

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000135378.3,PRRG4	BLCA	EHT.1864	EAG	4.1028e-04	-0.2565
chr11:32856848-32857461:+	BLCA	GSK269962A	EER	8.0116e-08	-0.4333
ENSG00000135378.3,PRRG4	BRCA	AZD.0530	EAG	1.4291e-04	-0.1552
chr11:32853548-32854557:+	BRCA	A.770041	EER	3.8217e-02	-0.1205
chr11:32856848-32857461:+	CESC	DMOG	EER	3.8624e-03	0.3256
ENSG00000135378.3,PRRG4	CESC	DMOG	EAG	1.5375e-03	0.3239
chr11:32856848-32857461:+	COAD	CCT007093	EER	1.2988e-05	-0.5192
ENSG00000135378.3,PRRG4	COAD	CCT007093	EAG	3.6358e-06	-0.5060
chr11:32853548-32854557:+	ESCA	CEP.701	EER	7.6498e-05	-0.4111
chr11:32856848-32857461:+	ESCA	KIN001.135	EER	6.6188e-03	0.2456
chr11:32856848-32857461:+	GBM	KIN001.135	EER	1.0823e-03	0.6369
ENSG00000135378.3,PRRG4	GBM	KIN001.135	EAG	4.3169e-04	0.6615
chr11:32856848-32857461:+	HNSC	FH535	EER	1.1276e-03	0.2715
chr11:32853548-32854557:+	HNSC	Bicalutamide	EER	4.8744e-03	0.3197
ENSG00000135378.3,PRRG4	HNSC	AZD7762	EAG	5.4919e-04	-0.2608
ENSG00000135378.3,PRRG4	KICH	AZD7762	EAG	5.0504e-03	0.6012
chr11:32853548-32854557:+	KIRC	DMOG	EER	6.1730e-04	0.2578
ENSG00000135378.3,PRRG4	KIRC	DMOG	EAG	9.2620e-05	0.2387
chr11:32856848-32857461:+	KIRC	BIRB.0796	EER	4.1155e-03	-0.1963
ENSG00000135378.3,PRRG4	KIRP	Bexarotene	EAG	1.7996e-02	0.2252
chr11:32853548-32854557:+	LIHC	CI.1040	EER	9.3464e-07	-0.4192
chr11:32856848-32857461:+	LIHC	Cisplatin	EER	1.2313e-04	-0.2474
ENSG00000135378.3,PRRG4	LIHC	CI.1040	EAG	2.4844e-07	-0.3111
chr11:32853548-32854557:+	LUAD	Lenalidomide	EER	1.9238e-02	-0.2271
chr11:32856848-32857461:+	LUAD	BX.795	EER	8.7470e-04	-0.2335
ENSG00000135378.3,PRRG4	LUAD	Lenalidomide	EAG	9.6182e-05	-0.2491
chr11:32856848-32857461:+	LUSC	Gefitinib	EER	1.1008e-02	0.1777
ENSG00000135378.3,PRRG4	LUSC	Lapatinib	EAG	3.0731e-03	0.1911
ENSG00000135378.3,PRRG4	OV	BMS.509744	EAG	9.0933e-08	-0.3456
chr11:32856848-32857461:+	OV	A.770041	EER	5.7353e-05	-0.2826
chr11:32853548-32854557:+	OV	BMS.509744	EER	3.6064e-06	-0.3646
chr11:32856848-32857461:+	PAAD	Lapatinib	EER	4.5839e-03	0.3064
ENSG00000135378.3,PRRG4	PAAD	Lenalidomide	EAG	3.2307e-03	-0.3007
ENSG00000135378.3,PRRG4	PCPG	BMS.754807	EAG	1.7230e-02	0.5259
ENSG00000135378.3,PRRG4	PRAD	AZD6482	EAG	2.7028e-08	0.4689
chr11:32856848-32857461:+	PRAD	AZD6482	EER	4.2480e-06	0.4416
ENSG00000135378.3,PRRG4	SARC	JNK.Inhibitor.VIII	EAG	3.4106e-03	0.4144
chr11:32856848-32857461:+	SARC	JNK.Inhibitor.VIII	EER	5.0259e-03	0.4250
chr11:32856848-32857461:+	SKCM	CGP.082996	EER	2.4570e-03	0.4552
ENSG00000135378.3,PRRG4	SKCM	Axitinib	EAG	1.5261e-02	-0.3317
chr11:32853548-32854557:+	STAD	GSK269962A	EER	1.6304e-02	-0.1648
chr11:32856848-32857461:+	STAD	BIBW2992	EER	8.8689e-04	0.2350
ENSG00000135378.3,PRRG4	STAD	AMG.706	EAG	2.9339e-04	-0.2183
chr11:32853548-32854557:+	THCA	IPA.3	EER	1.9601e-03	-0.2671
ENSG00000135378.3,PRRG4	THCA	IPA.3	EAG	2.5716e-05	-0.2457
chr11:32856848-32857461:+	THCA	BMS.754807	EER	7.1872e-04	-0.2300
ENSG00000135378.3,PRRG4	THYM	JNK.9L	EAG	1.8356e-03	0.4472
chr11:32853548-32854557:+	UCEC	BMS.754807	EER	8.7219e-04	-0.6233
ENSG00000135378.3,PRRG4	UCEC	FH535	EAG	4.0238e-06	0.5070
chr11:32856848-32857461:+	UCEC	Erlotinib	EER	4.6365e-04	-0.4381

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType